ScreenerHero

MBIOMustang Bio, Inc.

NAS · US · Healthcare · Biotechnology · mustangbio.com
0.5787USD+0.82%Mkt Cap: 4.39M $P/E: —

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap4.39M $
Enterprise Value-10.81M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-1.92M $
Revenue/Share—
Last Price0.5787 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.64
PEG—
EV/EBITDA3.08
EV/Revenue—
P/S—
P/B0.58
EPS (TTM)-0.42
EPS (Forward)-0.35
52W Range
0.52504% of range1.850
52W High1.850 USD
52W Low0.5250 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-20.16%
ROA-10.92%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.26M $
CapEx (TTM)—
FCF Margin—
FCF Yield-97.43%
Net Debt-15.15M $
Net Debt/EBITDA4.32
Balance Sheet
Debt/Equity0.00
Current Ratio1.97
Quick Ratio1.94
Book Value/Sh0.9960 USD
Cash/Share2.000 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateJan 16, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.6.73M
Float5.35M
Insiders8.02%
Institutions9.93%
Short Interest
Short Ratio1.6d
Short % Float0.82%
Short % Out.0.73%
Shares Short55.15K
Short (prev mo.)102.44K
Technical
SMA 500.6457 (-10.4%)
SMA 2000.8617 (-32.8%)
Beta2.05
S&P 52W Chg18.16%
Avg Vol (30d)32.93K
Avg Vol (10d)30.19K
Technical Indicators
RSI (14)42.9
MACD-0.0157
MACD Signal-0.0184
MACD Hist.+0.0026
BB Upper0.6222 USD
BB Middle0.5874 USD
BB Lower0.5527 USD
BB Width11.83%
ATR (14)0.0395 USD
Vol Ratio (20d)0.20x